Tag:OCT

European Cannabis Stocks Review: Akanda Reports $2.3m Loss From Bophelo, OCT Shares Spike & Cellular Goods Sales Slow

Akanda  Akanda unveiled its unaudited financial figures for the six months to the end of June 2022, two weeks after revealing that its CEO has...

Greencare Capital To ‘Withdraw’ From ‘Difficult’ Cannabis Market, OCT Shares Jump As New CEO Appointed, & More From MGC Pharma

Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has seen its share price jump by more than 20% this week after announcing that its CEO Dr...

European Cannabis Stocks Review: OCT Announces ‘Budget Review’ As Finance Director Quits, Tikun Olam Cannbit Receives EU GMP & More From IIROC

AFTER a month of relatively positive upwards trajectory for many European cannabis stocks, this week has seen a return to stagnation and decline, although...

Oxford Cannabinoid Technologies Releases Update On Its Two Lead Compounds

OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased...

OCT Co-Founder Publishes Scathing Letter Accusing Directors of ‘Serious Governance & Management’ Failings Ahead of GM Vote to Oust Board

GAVIN Sathianathan, a founder member of Oxford Cannabinoid Technologies (OCT), published a bombshell letter to fellow investors last week laying bare the numerous reasons...

EU Cannabis Stocks Review: OCT Board Accused of Serious Governance Issues by Co-Founder, Panaxia’s Debt Pile Hits Stock & More from Love Hemp

AS European Cannabis stocks continue their battle against external market forces, it has been internal battles which made the headlines this week.  Major stakeholders of...

Oxford Cannabinoid Technologies Says Data From Pre-Clinical Study of Leading Drug Candidate Shows Positive Results

OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased...

EU Cannabis Stocks Review: Love Hemp jumps 60%, OCT sees recovery & more from Cellular Goods, Chill Brands and MGC Pharma

On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets. 

Latest news

European Cannabis Stocks Review: Celadon Shares Spike 150% On Licence Update, OCT Continues Recovery, & Creso Pharma Censured By ASX

Celadon Pharmaceuticals  Celadon Pharmaceuticals stock has skyrocketed by more than 150% this week following the announcement that its current Home...
- Advertisement -spot_imgspot_img

Benefits of F1 Cannabis Hybrids from Royal Queen Seeds

F1 hybrids have revolutionised the way we grow and use plants. Now, F1 cannabis seeds are bringing growers, smokers,...

Celadon Pharmaceuticals Announces Home Office Approval Of Licence For Commercial Sale Of GMP Cannabis

PRESS RELEASE FURTHER to the announcement dated 16 January 2023, Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on...

Must read